Results 11 to 20 of about 1,506 (115)

Pharmacokinetic Drug-Drug Interaction Potential of Oral Anticancer Drugs. [PDF]

Clin Pharmacol Ther
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Alhurayri F, Younis IR, Jalal SI, Logan TF, Maniar R, Bray SM, Quinney SK, Desta Z, Skaar TC, Tisdale JE, Shugg T.   +10 more
europepmc   +2 more sources

From Real World Data to Real Impact: A Co-Medication Framework for Lung Cancer to Advance DDI Assessment and Patient-Centric Drug Development. [PDF]

Clin Transl Sci
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Biju M, Choi H, Madari S, Carlisle A, Sharma A, Kunz C, Huang F.   +6 more
europepmc   +2 more sources

Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics

Pharmaceutics
Pralsetinib is a kinase inhibitor indicated for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer.
Kit Wun Kathy Cheung, Yang Tang, Sravanthi Cheeti   +2 more
exaly   +3 more sources

Sequential targeted therapy in synchronous dual-primary lung adenocarcinomas with EGFR and RET alterations: a 5-year follow-up case report [PDF]

Frontiers in Oncology
With the increasing detection of multiple primary pulmonary nodules, accurately distinguishing between multiple primary lung cancers and intrapulmonary metastasis is crucial for diagnosis and treatment.
Yong-liang Niu, Ying Yang, Xiao-bao Teng, Ming-feng Han, Di-ming Wang   +4 more
doaj   +2 more sources

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC

JTO Clinical and Research Reports
Introduction: Pralsetinib is a RET inhibitor found to have antitumor activity in advanced, metastatic, RET fusion-positive NSCLC. Objective: To assess real-world efficacy of pralsetinib and treatment sequences in patients with RET fusion-positive NSCLC ...
Francesca Lucibello, MD, Valérie Gounant, MD, PhD, Mihaela Aldea, MD, PhD, Michaël Duruisseaux, MD, PhD, Maurice Perol, MD, Christos Chouaid, MD, Jaafar Bennouna, MD, PhD, Vincent Fallet, MD, Aldo Renault, MD, Florian Guisier, MD, PhD, Etienne Giroux-Leprieur, MD, PhD, Marie Wislez, MD, PhD, Anne-Claire Toffart, MD, PhD, Julien Mazieres, MD, PhD, Clémence Basse, MD, PhD, Nadia Hegarat, PhD, Matthieu Carton, MD, Nicolas Girard, MD, PhD   +17 more
exaly   +3 more sources

Effective treatment of non-fusion RET intragenic deletion lung adenocarcinoma with pralsetinib: a case report [PDF]

Frontiers in Medicine
RET fusions, the most common oncogenic RET alterations, occur in approximately 1–2% of non-small cell lung cancer (NSCLC) cases and represent well-established therapeutic targets.
Wenjun Li, Wenjun Zhu, Wenjun Zhu, Can Yang, Yaping Tian, Linna Cao, Lirong He   +6 more
doaj   +2 more sources

RET signaling as a mediator of estrogen receptor positive breast cancer brain metastasis [PDF]

Communications Biology
Brain metastasis (BrM) occurs in 10–15% of patients with estrogen receptor–positive breast cancer (ER + BC) and remains a major clinical challenge with limited therapeutic options.
Simeng Liu, Geoffrey Pecar, Ye Cao, Fangyuan Chen, Abdalla Wedn, Osama S. Shah, Jennifer M. Atkinson, Jagmohan Hooda, Steffi Oesterreich, Adrian V. Lee   +9 more
doaj   +2 more sources

Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer [PDF]

Frontiers in Oncology
The global incidence of thyroid cancer has increased significantly, and patients with advanced, recurrent, or radioiodine-refractory disease face a severe shortage of effective treatment options.
Yulu Zhou, Yulu Zhou, Junjie Cao, Siqi Zhang, Mingjun Sun, Yaqi Zhang, Songzhe Li, Zining Luo, Pengyu Wang, Jiebin Xie   +9 more
doaj   +2 more sources

Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer

Frontiers in Medicine
BackgroundPralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs).
Liang-Ping Xia
exaly   +3 more sources

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib [PDF]

Frontiers in Genetics
Anaplastic lymphoma kinase (ALK) fusion, an oncogenic driver alteration, accounts for 5%–6% of non-small cell lung cancer (NSCLC) patients. ALK tyrosine kinase inhibitors (TKIs) provide significant clinical benefit in advanced ALK-rearranged NSCLC ...
Feng Jin, Chenyang Wang, Fang Yang, Shubin Wang, Fen Wang   +4 more
doaj   +2 more sources